Skip to main content

Table 3 Key Indicators among pharmacies and private for-profit health facilities in PPM versus non-PPM districts

From: The malaria testing and treatment landscape in the southern Lao People’s Democratic Republic (PDR)

  PPM district outlets Non-PPM district outlets
%
(95% CI)
%
(95% CI)
Proportion of anti-malarial stockists with: N = 264 N = 101
Any national first-line ACT (AL) 68.1 2.5
(59.7, 75.4) (0.9, 6.8)
Chloroquine 63.6 96.7
(56.5, 70.2) (92.3, 98.6)
  N = 275 N = 110
Any confirmatory testing 72.6 12.1
(66.5, 78.0) (6.6, 21.0)
Proportion of providers frwho: N = 275 N = 110
Correctly state the national first-line treatment for uncomplicated P. falciparum/vivax malaria 65.0
(57.3, 72.0)
15.0
(7.6, 27.6)
Correctly state the first-line dosing regimen for uncomplicated P. falciparum/vivax malaria for an adult 51.0
(43.9, 58.0)
6.1
(2.7, 13.4)
  N = 155 N = 36
Report receiving a supervisory or regulatory visit within the past year 74.5
(61.6, 84.3)
17.0
(4.1, 49.4)
Median price Median
[IQR] (N of Anti-malarials)
Median
[IQR] (N of Anti-malarials)
National first-line ACT (AL) AETD # $0.00 $0.00
[0.00–0.00] (516) [0.00–0.00] (3)
Chloroquine AETD # $0.62 $0.62
[0.62–0.62] (173) [0.47–0.62] (103)
Rapid diagnostic test $0.00 $3.12
[0.00–0.25] (216) [2.50–3.75] (38)
  1. AL artemether–lumefantrine, AETD adult equivalent treatment dose, IQR interquartile range